(Q73707411)

English

A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen

scientific article published on 01 July 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

D Chao

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

M von Schlippe

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

S J Harland

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 July 1997

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

33

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1230-1233

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900097-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900097-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900097-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer: an Illinois cancer center study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900097-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Original article: Prognostic factors in hormone-resistant progressing cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900097-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900097-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900097-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900097-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900097-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(97)00097-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301448%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73707411&oldid=2034173397"